Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q2 2014 · 10-Q
Revenue$37.84K$37.84K−61.7% vs Q2 2013 Net Income-$58.15K-$58.15KN/M vs Q2 2013 EPS Diluted$0.00$0.00— vs Q2 2013 Gross Profit$25,843−53.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived-$48,418N/M Margins · derivedGross margin68.3%+12.4 pt vs Q2 2013
Operating margin-148.4%+490.3 pt vs Q2 2013
Net margin-153.7%+492.5 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 12, 2014 · 43 d after period end